<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20120122008801N24</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-07-24</date_registration>
      <primary_sponsor>Presidential Scientific and Technological Vice President</primary_sponsor>
      <public_title>The effect of training through the application on improving the quality of life of infertile women</public_title>
      <acronym></acronym>
      <scientific_title>The effect of training through the application on improving the quality of life of infertile women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-02-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64718</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: After obtaining informed consent and explaining the research objectives, all eligible women will be invited to the study and if they are willing and interested in participating in the study, they will be included in the research and will be randomly assigned to one of the control groups (n=50) and intervention (n=50) will be included. In this research, randomization into two groups will be done by the block randomization method. This way, 50 binary blocks will be considered in such a way that 25 blocks with order A and dimension B and another 25 blocks with order B and dimension A will be considered. Then, using the RAND() command in Excel software, 50 random numbers will be generated, and using these numbers, these 50 blocks will be sorted randomly. Then, the participants in the intervention group (A) and the control group (B) according to the order of visiting and in the order of A and B in each block. In this way, two groups of 50 people will be randomly assigned to intervention and control groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Infertility.</hc_freetext>
      <i_freetext>Intervention 1: In the "intervention group", before the intervention, the demographic information questionnaire and the questionnaire for the quality of life of infertile women will be completed by the participants. For the "intervention group", the application for improving the quality of life of infertile women contains 57 educational clips of 5 to 25 minutes in 7 areas of improving physical, mental, sexual, family-social health, adaptation, and overcoming obstacles of the adaptation and also the related concerns. The content will be prepared and validated by the experts of reproductive health and psychologist and designed as an application. This application will e installed and used by the participants of the intervention group for one months. The application will be designed by the computer department of Tarbiat Modares University, Tehran, Iran. Then, in order to determine the effectiveness of the intervention, the questionnaire for the quality of life of infertile women will be completed twice, once one month after use and again two months later. Intervention 2: In the "control group", the participants will receive the routine education and counseling services of the clinic and will not install the application. The participants of the "control group" will also complete the demographic questionnaire and as well as the questionnaire for the quality of life of infertile women at the beginning of the study.  in order to determine the effectiveness of the intervention, this group will also complete the questionnaire for the quality of life of infertile women twice, once after one month and once again after two months of routine interventions. The "control group" will receive the application for quality of life improvement after completing the study. In order to prevent the transfer of information between the intervention and control groups, the researcher will emphasize to the participants of the intervention group not to transfer information to the control group and reassure them about providing the content of the application to the "control group" after the completion of the study.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after de-identifying individuals

When:
The access period starts 6 months after the results are published

To whom:
Researchers working in academic and scientific institutions

Conditions:
The data can be obtained by requesting from the main researcher and obtaining permission from Shahid Beheshti University of Medical Sciences with the confidentiality of the names of the individuals.

Where to obtain:
Dr. Masoumeh Simbar
Midwifery and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Cross of Vali-Asr and Hashemi Rafsanjani Highway, Opposite to Rajaee Heart Hospital, Tehran, Iran
Tel:۰۲۱۸۸۲۰۲۵۱۲
Postal Code: ۱۹۹۶۸۳۵۱۱۹

 Fax: ۰۰۹۸۲۱ ۸۸۶۵۵۳۷۶

How to obtain:
Request from the principal investigator, obtaining permission from Shahid Beheshti University of Medical Sciences

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Masoumeh Simbar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Midwifery and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Cross of Vali-Asr and Hashemi Rafsanjani Highway, Opposite to Rajaee Heart Hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۹۹۶۸۳۵۱۱۹</zip>
        <telephone>+98 21 8820 2512</telephone>
        <email>msimbar@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Masoumeh Simbar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Reproductive Health and Midwifery, Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences (3th floor, Deputy of research), Vali-Asr Avenue, Cross of Vali-Asr and Neiaiesh Highway, Opposite to Rajaee Heart Hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1996835119</zip>
        <telephone>+98 21 8820 2517</telephone>
        <email>msimbar@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of infertility with the opinion of a gynecologist
Diagnosis of infertility with the opinion of a gynecologist
official marriage
No bereavement experience in the last 6 months</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Lack of informed consent</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N97</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Female infertility</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the "intervention group", before the intervention, the demographic information questionnaire and the questionnaire for the quality of life of infertile women will be completed by the participants. For the "intervention group", the application for improving the quality of life of infertile women contains 57 educational clips of 5 to 25 minutes in 7 areas of improving physical, mental, sexual, family-social health, adaptation, and overcoming obstacles of the adaptation and also the related concerns. The content will be prepared and validated by the experts of reproductive health and psychologist and designed as an application. This application will e installed and used by the participants of the intervention group for one months. The application will be designed by the computer department of Tarbiat Modares University, Tehran, Iran. Then, in order to determine the effectiveness of the intervention, the questionnaire for the quality of life of infertile women will be completed twice, once one month after use and again two months later.</i_keyword>
      <i_keyword>In the "control group", the participants will receive the routine education and counseling services of the clinic and will not install the application. The participants of the "control group" will also complete the demographic questionnaire and as well as the questionnaire for the quality of life of infertile women at the beginning of the study.  in order to determine the effectiveness of the intervention, this group will also complete the questionnaire for the quality of life of infertile women twice, once after one month and once again after two months of routine interventions. The "control group" will receive the application for quality of life improvement after completing the study. In order to prevent the transfer of information between the intervention and control groups, the researcher will emphasize to the participants of the intervention group not to transfer information to the control group and reassure them about providing the content of the application to the "control group" after the completion of the study.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Quality of life of infertile women. Timepoint: Measuring the quality of life of infertile women at the beginning of the study (before the start of the intervention), one month and two months after using the application. Method of measurement: Questionnaire of quality of life of infertile women.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Presidential Scientific and Technological Vice President</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-06-21</approval_date>
        <contact_name>Research Ethics Committees of School of Pharmacy and Nursing &amp; Midwifery- Shahid Beheshti University</contact_name>
        <contact_address>Midwifery and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Cross of Vali-Asr and Hashemi Rafsanjani Highway, Opposite to Rajaee Heart Hospital, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
